Association of <i>GRIA3</i> (rs12557782) Polymorphism with Interferon Beta Resistance Among Multiple Sclerosis Patients from Qazvin Province, Iran

Abstract

Background: Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS). The Interferon beta (IFN-β) therapy is one of the best ways to reduce the recurrence disease. However, response to IFN-β treatment may be related to genetic factors. The glutamate ionotropic receptor AMPA type subunit 3 (GRIA3) gene that located on Xq25_26, encodes a protein play a role in the genetic susceptibility of a variety of mental disorders. Objectives: This study aimed to investigate the association between GRIA3 rs12557782 polymorphism and resistance to IFN-β treatment in Iranian MS patients, specifically focusing on patients from Qazvin province with distinct genetic and environmental characteristics. Methods: In this clinical study, 155 Iranian patients with MS were selected based on the Expanded Disability Status Scale (EDSS) and the number of disease relapses over six months. They were divided into responders and non-responders groups to IFN-β treatment. Variations of rs12557782 polymorphism in GRIA3 and its relation to the treatment of patients with IFN-β drugs was evaluated by PCR-RFLP technique and restriction enzyme DraII. Results: No significant correlation was found between response to treatment with IFN-β drugs and polymorphism of rs12557782 in GRIA3. Conclusions: No significant association was observed between GRIA3 rs12557782 polymorphism and resistance to IFN-β treatment in Iranian MS patients from Qazvin province.